Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was founded in 2015 and is headquartered in Seongnam, Korea.
तुलना करने के लिए मीट्रिक्स | 288330 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध288330पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.0x | −4.6x | −0.5x | |
PEG अनुपात | −0.03 | 0.01 | 0.00 | |
क़ीमत/बुक | 1.5x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 17,732.7x | 9.7x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 52.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.9% | 7.6% | अनलॉक करें |